NPI: 1730128836 · MIDWEST CITY, OK 73110 · Cardiovascular Disease Physician · NPI assigned 06/05/2006
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR) |
| NPI Enumeration Date | 06/05/2006 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 23,959 | $1.57M |
| 2019 | 18,915 | $1.45M |
| 2020 | 15,138 | $1.33M |
| 2021 | 11,496 | $941K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 9,884 | 9,623 | $2.16M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 8,790 | 8,586 | $1.27M |
| D9999 | Unspecified adjunctive procedure, by report | 462 | 462 | $411K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3,440 | 3,343 | $407K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 768 | 761 | $213K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,675 | 1,621 | $127K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,489 | 1,480 | $126K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,279 | 2,186 | $87K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1,416 | 1,400 | $73K |
| 80053 | Comprehensive metabolic panel | 6,504 | 6,342 | $64K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,270 | 1,258 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6,996 | 6,790 | $52K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,307 | 1,272 | $50K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,641 | 1,632 | $34K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 299 | 194 | $30K |
| 71045 | Radiologic examination, chest; single view | 1,604 | 1,590 | $17K |
| 87400 | 1,321 | 1,315 | $16K | |
| 81001 | 4,914 | 4,763 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | 837 | 829 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 101 | 101 | $10K |
| 85027 | 1,111 | 1,071 | $7K | |
| 36415 | Collection of venous blood by venipuncture | 2,806 | 2,613 | $6K |
| 80055 | 131 | 131 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | 359 | 358 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 373 | 372 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 63 | 63 | $5K |
| 83690 | 571 | 551 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 120 | 120 | $3K |
| 80061 | Lipid panel | 212 | 212 | $3K |
| 84703 | 374 | 368 | $3K | |
| 87081 | 306 | 305 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 217 | 216 | $2K |
| 84439 | 209 | 209 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | 45 | 45 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 12 | 12 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 50 | 49 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 227 | 220 | $2K |
| 97597 | 85 | 51 | $919.78 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 14 | 14 | $718.34 |
| 83735 | 106 | 103 | $643.94 | |
| 82247 | 124 | 76 | $590.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,366 | 1,320 | $580.35 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 29 | 28 | $450.94 |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13 | 12 | $437.43 |
| 84484 | 26 | 25 | $433.25 | |
| 83880 | 12 | 12 | $420.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 403 | 403 | $316.33 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 13 | 13 | $148.24 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18 | 12 | $87.12 |
| 82950 | 16 | 16 | $77.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 513 | 463 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 12 | 12 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 392 | 392 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 530 | 529 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 214 | 214 | $0.00 |
| 36416 | 18 | 15 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 443 | 443 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 784 | 756 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 152 | 141 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 12 | 12 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 18 | 15 | $0.00 |